Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy

Pediatric Blood and Cancer

Volumn 43, Issue 1, 2004, Pages 46-54

  Jennings, Mark T ^a,c   Cmelak, Anthony ^a   Johnson, Mahlon D ^a   Moots, Paul L ^a   Pais, Ray ^b   Shyr, Yu ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c Children's Hospital of Illinois   (United States)

Author keywords

Anaplastic ependymoma; Chemotherapy; Hyperfractionated radiotherapy; Malignant glioma; Medulloblastoma; Pediatric brain tumors; Primitive neuroectodermal tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; VINCRISTINE;

ACUTE MYELOMONOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TOXICITY; BRAIN TUMOR; CELLULITIS; CHILD; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; DOSE RESPONSE; EPENDYMOMA; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; MALE; MEDULLOBLASTOMA; MENINGITIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROECTODERM TUMOR; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMEMBRANOUS COLITIS; RADIATION DOSE FRACTIONATION; SEPSIS; SHUNT INFECTION; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR BIOPSY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; GLIOMA; HUMANS; MALE; NEOADJUVANT THERAPY; NEUROECTODERMAL TUMORS, PRIMITIVE; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; VINCRISTINE;

EID: 2942596421     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20043     Document Type: Article

References (38)

1. Norton L, Simon R. Tumor size, sensitivity to chemotherapy, and the design of treatment schedules. Cancer Treat Rep 1977;61: 1307-1317.
2. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. J Neurosurg 1993;78:767-775.
3. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiotherapy in children less than 3 years of age with malignant brain tumors. N Engl J Med 1993; 328:1725-1731.
4. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood highgrade astrocytoma comparing vincristine, lomustine, and prednisone with the eight drugs in 1 day regimen. J Clin Oncol 1995;13:112-123.
5. Albright AL, Wisoff JH, Zeltzer PM, et al. Effects of medulloblastoma resections on outcome in children: A report from the Children's Cancer Group. Neurosurgery 1996;38:265-271.
6. Campbell JW, Pollack IF, Martinez AJ, et al. High-grade astrocytomas in children: Radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 1996; 38:258-264.
7. Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: A report of the Children's Cancer Group trial No. CCG-945. J Neurosurg 1998; 89:52-59.
8. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-845.
9. Shapiro WR. Treatment of neuroectodermal brain tumors. Ann Neurol 1982;12:231-237.
10. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338-343.
11. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biology Phys 1993;26:239-244.
12. White L, Kellie S, Gray E, et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: Promising initial response to a VETOPEC-based regimen. J Pediatr Hematol Oncol 1998;20:125-130.
13. Shapiro WR. Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 1986;13:38-45.
14. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71:1-9.
15. Kortmann R-D, Kühl J, Timmerman B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT'91. Int J Radiat Oncol Biol Phys 2000;46:269-279.
16. Boiardi A, Silvani A, Milanesi I, et al. Primary glial tumor patients treated by combining cis-platin and etoposide. J Neurooncol 1991;11:165-170.
17. Jennings MT, Sposto R, Vezina LG, et al. Preradiation chemotherapy in primary high risk brain stem tumors: CCG-9941, a phase II study of the Children's Cancer Group. J Clin Oncol 2002;20:3431-3437.
18. Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Children's Cancer Group randomized trial. J Clin Oncol 1995;13:1687-1696.
19. Park JR, Slattery J, Gooley T, et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/ recurrent pediatric solid tumors. Med Pediatr Oncol 2000;35:719-723.
20. Kushner BH, Cheung N-KV, Kramer K, et al. Topotecan combined with myelablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 2001;28:551-556.
21. Jennings MT, Jennings VDL, Asadourian LLH, et al. Five novel cell surface antigens of CNS neoplasms. J Neurol Sci 1989; 89:63-78.
22. Ryan HE, Lo J, Johnson RS. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17: 3005-3015.
23. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Rep 1979;63:1727-1733.
24. Biegel JA. Genetics of pediatric central nervous system tumors. J Pediatr Hematol Oncol 1997;19:492-501.
25. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139-146.
26. Prados MD, Krouwer HGJ, Edwards MSB, et al. Proliferative potential and outcome in pediatric astrocytic tumors. J Neurooncol 1992;13:277-282.
27. Reavey-Cantwell JR, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: Analysis of 32 patients and review of the literature. J Neurooncol 2001;55:195-204.
28. Pollack IF, Hamilton RL, Burnham J, et al. Impact of proliferation index on outcome in childhood malignant gliomas: Results in a multiinstitutional cohort. Neurosurgery 2002;50:1238-1244.
29. Ito S, Hoshino T, Prados MD, et al. Cell kinetics of medulloblastomas. Cancer 1992;70:671-678.
30. Brown JM, Giaccia AJ. Tumour hypoxia: The picture has changed in the 1990s. Int J Radiat Oncol Biol Phys 1994;65:95-102.
31. Green SL, Giaccia AJ. Tumor hypoxia and the cell cycle: Implications for malignant progression and response to therapy. Cancer J 1998;4:214-223.
32. Graeber TC, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-91.
33. Liang BC. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 1996;29:149-155.
34. Henson JW, Cordon-Cardo C, Posner JB. P-glycoprotein expression in brain tumors. J Neurooncol 1992;14:37-43.
35. Takamiya Y, Abe Y, Tanaka Y, et al. Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts. Br J Cancer 1997;76:445-450.
36. Feun LG, Savaraj N, Landy HJ. Drug resistance in brain tumors. J Neurooncol 1994;20:165-176.
37. Ashmore SM, Thomas DGT, Darling JL. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? Anti-Cancer Drugs 1999;10:861-872.
38. Goldstein LJ. Clinical reversal of drug resistance. Curr Probl Cancer 1995;19:65-124.